DayOne Innovation Showcase 2026 Conference DayOne Innovation Showcase 2026 – – BoothDanielle PillsburyNovember 16, 2026
Accelerating GLP-1 Drug Development: How Metsera, Certara & Altasciences Reached Phase 2 Case Study Accelerating GLP-1 Drug Development: How Metsera, Certara & Altasciences Reached Phase 2 See how Metsera, Certara, and Altasciences built an integrated MIDD partnership to advance GLP-1 programs…CertaraNovember 12, 2026
From PK Data to Document: An AI-Driven Daytrip with Phoenix Cloud Webinar From PK Data to Document: An AI-Driven Daytrip with Phoenix Cloud Arjen BosOctober 30, 2026
2nd Model-Informed Drug Development Summit Conference 2nd Model-Informed Drug Development Summit –sarah CarrOctober 13, 2026
Population Pharmacokinetics of Dolutegravir in Plasma and Cerebrospinal Fluid in Adults Living With HIV Publication Population Pharmacokinetics of Dolutegravir in Plasma and Cerebrospinal Fluid in Adults Living With HIV Explore population PK modeling of dolutegravir in plasma and cerebrospinal fluid to characterize CNS penetration…CertaraOctober 5, 2026
Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Relapsed/Refractory Multiple Myeloma Publication Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Relapsed/Refractory Multiple Myeloma Explore a simultaneous population PK/PD model characterizing the dynamic relationships between belantamab mafodotin, sBCMA, and…CertaraOctober 5, 2026
How Do You Know You Have the Right Dose? Using Exposure-Response Evidence to Justify and Defend Dose Decisions Webinar How Do You Know You Have the Right Dose? Using Exposure-Response Evidence to Justify and Defend Dose Decisions Danielle PillsburyOctober 1, 2026
Enable AI to Access your PK Data: What’s New in Integral 7.1 Webinar Enable AI to Access your PK Data: What’s New in Integral 7.1 CertaraSeptember 24, 2026
Modeling effective doses of therapeutic antibodies targeting clustered surface receptors Publication Modeling effective doses of therapeutic antibodies targeting clustered surface receptors Discover how semi-mechanistic PK/receptor-occupancy modeling reveals that lower, subcutaneous doses, not maximum tolerated doses, optimize…Danielle PillsburySeptember 23, 2026